
    
      Phase I: Dose escalation in any 3+ HER2-positive solid tumor.

      Phase II: Dose expansion cohorts: 3+ HER2-positive breast cancer (a) and other solid tumors
      (b) 2+HER2-positive solid tumors (c).
    
  